Cresco Labs CEO: Rescheduling Ushers in a New Era of Care for Medical Cannabis Patients
CHICAGO — Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell in response to the Department of Justice’s final rule publication rescheduling medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. “Rescheduling medical cannabis […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.